PI4K2B: A Target for Cancer and Neurodegenerative Diseases (G55300)

Target Name: PI4K2B

NCBI ID: G55300

PI4K2B

PI4K2B: A Target for Cancer and Neurodegenerative Diseases

Phosphatidylinositol 4-kinase (PI4K2B) is a protein that plays a crucial role in cellular signaling, particularly in the regulation of intracellular signaling pathways. It is a key enzyme in the PI4K2A complex, which is involved in the phosphorylation of various protein substrates, including phosphatidylinositol (Ptd), a key intracellular signaling molecule. PI4K2B is a transcript variant of the PI4K2A gene and is expressed in various cell types.

The PI4K2A complex is involved in various cellular signaling pathways, including cell growth, differentiation, and survival. The PI4K2A signaling pathway is also implicated in the regulation of pain perception, inflammation, and neurodegenerative diseases.

PI4K2B as a drug target

The PI4K2B enzyme has been identified as a potential drug target in various diseases, including cancer and neurodegenerative diseases. Several studies have shown that PI4K2B is involved in the regulation of various cellular processes, including cell signaling, angiogenesis, and neurodegeneration.

In cancer, PI4K2B has been shown to be involved in the regulation of cell growth, angiogenesis, and the development of cancer stem cells. It has also been shown to play a role in the regulation of cell-cycle progression and the association with various types of cancer, including breast, ovarian, and colorectal cancer.

In neurodegenerative diseases, PI4K2B has been shown to be involved in the regulation of neurotransmitter synthesis, synaptic plasticity, and neurodegeneration. It has also been implicated in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

PI4K2B as a biomarker

PI4K2B has also been shown to be a potential biomarker for various diseases, including cancer and neurodegenerative diseases. The PI4K2B gene has been shown to be expressed in various tissues and cells, including cancer cells, neurotransmitter-producing cells, and brain cells.

Studies have shown that PI4K2B levels are often elevated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, PI4K2B has been shown to be involved in the regulation of neurotransmitter synthesis and release, which could make it an attractive biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

PI4K2B is a protein that plays a crucial role in cellular signaling and has been implicated in various diseases, including cancer and neurodegenerative diseases. Its role in the regulation of intracellular signaling pathways makes it an attractive target for drug development. Further research is needed to fully understand the role of PI4K2B in cellular signaling and its potential as a biomarker for various diseases.

Protein Name: Phosphatidylinositol 4-kinase Type 2 Beta

Functions: Together with PI4K2A and the type III PI4Ks (PIK4CA and PIK4CB) it contributes to the overall PI4-kinase activity of the cell (PubMed:11923287, PubMed:12324459). This contribution may be especially significant in plasma membrane, endosomal and Golgi compartments (PubMed:11923287, PubMed:12324459). The phosphorylation of phosphatidylinositol (PI) to PI4P is the first committed step in the generation of phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the second messenger inositol 1,4,5-trisphosphate (InsP3) (PubMed:11923287, PubMed:12324459). Contributes to the production of InsP3 in stimulated cells and is likely to be involved in the regulation of vesicular trafficking

The "PI4K2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PI4K2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets